The prognostic role of miR-31 in head and neck squamous cell carcinoma: systematic review and meta-analysis with trial sequential analysis
Are Retatrutide and Tirzepatide approved for research use
Primary research: Type 2 diabetes, obesity, metabolic disease Mechanism: Dual activation of GIP and GLP-1 receptors for enhanced metabolic effects Regulatory status: FDA-approved (Mounjaro 2022, Zepbound 2023) Key data: Up to 22.5% weight loss in SURMOUNT trials
In male animals, GHK-Cu treatment after toxic exposure has restored sperm motility and reduced DNA fragmentation in some reports
The science shows that it can reduce pain and improve nerve function, but the success of the treatment depends on using the correct type of light, the right dose, and the proper number of sessions
An approved drug label with formal contraindications does not yet exist for CagriSema